1. Introduction {#sec1-nutrients-12-02174}
===============

Type 2 diabetes mellitus (T2DM) has a close relationship with multiple organ abnormalities and various pathophysiological abnormalities, such as metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) \[[@B1-nutrients-12-02174]\], arthritis \[[@B2-nutrients-12-02174]\], sleep apnea \[[@B3-nutrients-12-02174]\] and cardiovascular disease (CVD) \[[@B4-nutrients-12-02174]\]. NAFLD is characterized by intrahepatic ectopic fat accumulation due to insulin resistance and abdominal obesity, and the presence of NAFLD correlates with visceral, intramuscular, epicardial, and perivascular fat accumulation \[[@B5-nutrients-12-02174],[@B6-nutrients-12-02174]\]. The frequency of NAFLD is particularly high in people with T2DM; it has been reported that about 50 to 60% of patients with T2DM have NAFLD \[[@B7-nutrients-12-02174],[@B8-nutrients-12-02174]\]. Longitudinal studies suggest a strong bidirectional relationship between NAFLD and type 2 diabetes \[[@B1-nutrients-12-02174]\].

Lifestyle, including eating habits, is an important factor for NAFLD. Excessive energy intake has been reported to be an important factor in increasing the fat content of the liver \[[@B7-nutrients-12-02174]\]. In addition, eating fast is known to be associated with overweight and obesity in adults \[[@B9-nutrients-12-02174],[@B10-nutrients-12-02174],[@B11-nutrients-12-02174]\]. According to previous studies on eating behavior, eating slowly is associated with lower energy intake in comparison to eating fast \[[@B12-nutrients-12-02174],[@B13-nutrients-12-02174]\]. Eating speed is related to the number of chews; an increased number of chews reduces body weight \[[@B9-nutrients-12-02174]\] by increasing satiety \[[@B14-nutrients-12-02174]\] and reduces meal consumption \[[@B15-nutrients-12-02174]\]. Besides, eating speed is reported to be associated with insulin resistance \[[@B16-nutrients-12-02174]\]. Moreover, it has been shown that eating fast is associated with metabolic syndrome \[[@B10-nutrients-12-02174],[@B17-nutrients-12-02174]\] and T2DM \[[@B16-nutrients-12-02174],[@B18-nutrients-12-02174]\]. Furthermore, several studies have also revealed that eating fast is associated with NAFLD in the general population \[[@B19-nutrients-12-02174],[@B20-nutrients-12-02174],[@B21-nutrients-12-02174]\]. However, the association between eating speed and NAFLD in patients with T2DM has not been established. Moreover, the influence of the sex of the patient on this association is another important factor, which has not yet been studied. Therefore, we aimed to determine the correlation between eating speed and NAFLD in men and women with T2DM, separately in this cross-sectional study.

2. Methods {#sec2-nutrients-12-02174}
==========

2.1. Study Participants {#sec2dot1-nutrients-12-02174}
-----------------------

We are carrying out an ongoing prospective cohort study, we named this cohort study as the KAMOGAWA-DM cohort study, since 2014 to clarify the natural history of people with diabetes \[[@B22-nutrients-12-02174]\]. This study included the outpatients of the Department of Endocrinology and Metabolism at Kyoto Prefectural University of Medicine Hospital (Kyoto, Japan) and the Department of Diabetology at Kameoka Municipal Hospital (Kameoka, Japan). In this study, we included patients who answered questionnaires from January 2016 to December 2018. We excluded patients with the following characteristics: viral hepatitis, liver cancer, missing laboratory data, non-T2DM, alcohol ≥20 g/day \[[@B23-nutrients-12-02174]\], and incomplete questionnaires. This study was approved by the local research ethics committee (No. RBMR-E-466-5) and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all the patients.

2.2. Lifestyle Characteristics and Measurement {#sec2dot2-nutrients-12-02174}
----------------------------------------------

Physical activity and smoking status were evaluated by using the questionnaire. Habit of smoking was defined as current smoker or not. Habit of exercise was defined as performing any kind of physical activity at least once a week. Furthermore, the duration of diabetes was also asked for all patients.

We collected the venous blood after overnight fasting and checked the following factors: hemoglobin A1c (assayed by high-performance liquid chromatography), plasma glucose, total cholesterol, triglycerides gamma-glutamyl transpeptidase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST).

Body mass index (BMI) was calculated as the weight in kilograms divided by height in meters squared. Ideal body weight (IBW) was calculated as 22 multiplied by the square of patient's height in meters squared \[[@B24-nutrients-12-02174]\]. When the self-reports of dietary intake were performed, blood pressures were measured using a HEM-906 device (OMRON, Kyoto, Japan) in a quiet space after 5 min of rest. The data regarding antidiabetic medication were also obtained from medical records.

2.3. Questionnaire for Dietary Habit {#sec2dot3-nutrients-12-02174}
------------------------------------

Brief-type self-administered diet history questionnaire (BDHQ) was used for evaluating patients' habitual food and nutrient intake during the previous month. The details and validity of the BDHQ were reported previously \[[@B25-nutrients-12-02174]\]. Patient data on energy intake, carbohydrate intake, protein intake, fat intake, fiber intake, and alcohol consumption were collected using the BDHQ. Energy intake (kcal/kg IBW/day) was calculated as dietary total energy (kcal/day) divided by IBW (kg). Carbohydrate/fiber intake was also calculated as carbohydrate intake divided by fiber intake \[[@B26-nutrients-12-02174]\].

Eating speed was evaluated by the following statements: very fast, a little fast, normal, a little slow, or very slow, and then we defined "very fast" or "a little fast" as "fast speed eating," "normal" as "moderate speed eating," and "very slow" or "a little slow" as "slow speed eating."

2.4. Definition of NAFLD {#sec2dot4-nutrients-12-02174}
------------------------

In this study, we excluded patients who drunk alcohol ≥20 g/day \[[@B23-nutrients-12-02174]\]. Hepatic steatosis index (HSI) was used for the presence of NAFLD. The formula of HSI \[[@B27-nutrients-12-02174]\] was follows: HSI = 8 × (ALT/AST) + BMI (+2, if impaired fasting glucose (all patients had diabetes in this study); +2, if female). In this study, NAFLD was defined as HSI ≥ 36 points.

2.5. Statistical Analysis {#sec2dot5-nutrients-12-02174}
-------------------------

We performed statistical analyses using EZR (version 1.40) (Saitama Medical Center, Jichi Medical University, Saitama, Japan) \[[@B28-nutrients-12-02174]\], and *p*-value \< 0.05 was considered to be statistically significant. Continuous variables were described as the mean (± standard deviation) and categorical variables were described as the number. Since the characteristics and dietary intake were different for men and women, we separately analyzed the patients by sex.

The differences in characteristics and dietary intake among the patients with different eating speeds were evaluated by the Kruskal-Wallis test and Steel-Dwass test or chi-squared test.

We then performed logistic regression analyses to examine the effects of eating speed on the presence of NAFLD. The following factors were considered as independent variables: sex, age, duration of diabetes, hemoglobin A1c, insulin treatment, energy intake, carbohydrate intake, dietary fiber intake, habit of exercise, and habit of smoking. BMI is a risk factor for NAFLD \[[@B29-nutrients-12-02174]\]. However, BMI was already included the components of HSI; thus, we did not include BMI in the covariates.

3. Results {#sec3-nutrients-12-02174}
==========

In the present study, 425 patients (234 men and 191 women) were included. We excluded 117 patients: 10 patients had viral hepatitis, 1 patient had liver cancer, 42 patients did not have T2DM, 42 patients had a habit of alcohol consumption, 21 patients did not complete the questionnaires and one patient did not perform laboratory examination; therefore, the final study population included 308 patients (149 men and 159 women) ([Figure 1](#nutrients-12-02174-f001){ref-type="fig"}).

The characteristics and dietary intake of study patients are shown in [Table 1](#nutrients-12-02174-t001){ref-type="table"}. Mean age, BMI and HSI were 66.8 ± 10.6 years, 24.2 ± 4.0 kg/m^2^ and 35.3 ± 5.9 points, respectively, in all subjects. The proportion of NAFLD was 36.7% and the proportions of fast, moderate and slow eating were 42.1%, 36.6% and 21.6%, respectively, in all subjects. Furthermore, mean HSI of women (36.4 ± 6.7 points) was higher than that of men (34.2 ± 4.8 points) (*p* = 0.006), and the percentage of the presence of NAFLD of women (43.4%) was higher than that of men (29.5%) (*p* = 0.016). On the other hand, the percentage of patients eating fast was not differ between men and women. In addition, the carbohydrate/fiber intake of men (20.4 ± 7.6) was higher than that of women (17.7 ± 6.0) (*p* \< 0.001).

The characteristics of patients according to their eating speed are shown in [Table 2](#nutrients-12-02174-t002){ref-type="table"}. In the case of men, patients eating fast had a higher BMI (*p* = 0.007) and were younger (*p* = 0.009) than the patients eating slowly. Although energy intake (kcal/kg IBW/day) was not different among the groups, carbohydrate/fiber intake of patients eating fast was higher than that of patients eating slowly. The percentages of the presence of NAFLD in patients with fast, moderate, and slow eating speeds were 37.3%, 27.1%, and 11.5%, respectively. However, in women there was no difference in age, BMI, and nutrient parameters among the groups. The percentages of the presence of NAFLD in patients with fast, moderate, and slow eating speeds were 47.1%, 43.8%, and 32.0%, respectively.

The odds ratios (ORs) for the presence of NAFLD across the three categories of eating speeds (fast, moderate, and slow) are shown in [Table 3](#nutrients-12-02174-t003){ref-type="table"}. Compared with eating slowly, easting fast tended to be associated with the presence of NAFLD in both men and women (OR 2.10, 95% 95% confidence interval (CI) 0.90--4.91, *p* = 0.087), although it did not reach statistically significance. Compared with eating slowly, eating fast had an elevated risk of the presence of NAFLD after adjusting for covariates (OR 4.48, 95% CI1.09--18.5, *p* = 0.038) in men. In contrast, there was no relationship between eating speed and the risk of the presence of NAFLD in women. However, fiber intake (OR 0.85, 95% Cl 0.76--0.96, *p* = 0.010) was negatively associated and energy intake (OR 1.05, 95% Cl 1.00--1.10, *p* = 0.044) was positively associated with the presence of fatty liver in women.

4. Discussion {#sec4-nutrients-12-02174}
=============

This is the first study that investigates the association between eating speed and the presence of NAFLD in patients with T2DM in men and women separately. The results of this study show that eating speed is associated with the presence of NAFLD in men but not in women.

In this study, 47.1% of the participants were categorized as "eating fast". There is a possibility that patients withT2DM might eat faster than apparently healthy subjects. In fact, a previous study reported that the prevalence of eating fast in patients with diabetes was 61.5% \[[@B30-nutrients-12-02174]\], which was higher than that in healthy subjects \[[@B16-nutrients-12-02174],[@B18-nutrients-12-02174]\]. In addition, in this study, eating fast was associated with NAFLD in men, which is the same as previous studies \[[@B19-nutrients-12-02174],[@B20-nutrients-12-02174],[@B21-nutrients-12-02174]\]. On the other hand, eating speed was not association with the presence of NAFLD in women. This result is a new finding, because the association between NAFLD and eating speed by sex was not evaluated, previously.

Eating fast is known to be associated with overweight and obesity \[[@B9-nutrients-12-02174],[@B10-nutrients-12-02174],[@B11-nutrients-12-02174]\], insulin resistance \[[@B16-nutrients-12-02174]\], metabolic syndrome \[[@B10-nutrients-12-02174],[@B17-nutrients-12-02174]\] and T2DM \[[@B16-nutrients-12-02174],[@B18-nutrients-12-02174]\]. Eating fast is also reported to be associated with a risk factor for CVD \[[@B31-nutrients-12-02174]\], which is associated with NAFLD \[[@B4-nutrients-12-02174],[@B32-nutrients-12-02174]\].

The possible explanations for the association between eating speed and NAFLD are as follows. The action of chewing results in biting down of the food particles, not only aiding digestion and absorption in the stomach and intestines but also stimulates the satiety center and prevents appetite \[[@B14-nutrients-12-02174],[@B33-nutrients-12-02174]\]. Chewing well over time also activates the brain, which releases more neuronal histamine and makes the person feel fuller \[[@B34-nutrients-12-02174]\]. Neuronal histamine is thought to stimulate the satiety center and sympathetic nerves. Additionally, ghrelin, GLP-1, and peptide YY (PYY) act on the hypothalamus and play a role in the regulation of hunger, satiety, and energy intake \[[@B35-nutrients-12-02174]\]. Recently, a study suggested that eating slowly increases the postprandial response of GLP-1 and PYY \[[@B35-nutrients-12-02174],[@B36-nutrients-12-02174]\]. These results suggest that patients who eat fast may have a lower secretion of GLP-1 and PYY, which may lead to a higher energy intake because they do not feel satiated. Although the difference is not statistically significant, the energy intake in case of patients who ate fast was higher than that of others in men. Hence, it is quite possible that patients who eat fast under-reported their food intake. Since the BDHQ is based on the self-reported frequency of intake, there is a possibility that the answer might not be the actual intake, especially for obese individuals. It has been previously reported that obese individuals tend to under-report their food intake \[[@B37-nutrients-12-02174]\]. Moreover, eating slowly might inhibit the secretion of excess insulin because of slower absorption of nutrients. A previous study revealed that the plasma concentrations of insulin were reduced by α-glucosidase inhibition, which slowed down absorption in the intestines \[[@B38-nutrients-12-02174],[@B39-nutrients-12-02174]\]. Eating fast causes a rapid rise in blood sugar levels and insulin is excessively secreted. Thus, this effect may have facilitated fat accumulation in the liver.

Another possible mechanism is diet-induced thermogenesis (DIT). DIT is the increase in energy expenditure associated with the digestion, absorption, and storage of food and accounts for approximately 10--15% of total daily energy expenditure \[[@B40-nutrients-12-02174]\]. Eating slowly is reported to enhance DIT \[[@B40-nutrients-12-02174],[@B41-nutrients-12-02174]\].

Eating speed was associated with carbohydrate/fiber intake in men. Previous studies revealed that carbohydrate/fiber intake is associated with metabolic syndrome \[[@B27-nutrients-12-02174]\] and visceral fat accumulation \[[@B42-nutrients-12-02174]\]. Thus, there is a possibility that poor diet quality in men with the habit of fast eating is the cause of the presence of NAFLD. In contrast, we did not find an association between eating speed and the presence of NAFLD in women. One of the possible reasons is that eating speed in this study was self-reported, and the difference in eating speed would be small in women. In fact, an earlier study has reported that eating speed is slower in women than in men \[[@B43-nutrients-12-02174]\]. Another point to be considered is the diet quality. In this study, energy intake and dietary fiber intake were found to be associated with the presence of NAFLD in women. Excessive energy intake has been reported to be an important factor in increasing the fat content of the liver \[[@B7-nutrients-12-02174]\]. Moreover, dietary fiber intake was found to be associated with the presence of NAFLD. Poor dietary fiber intake promotes the development of NAFLD \[[@B44-nutrients-12-02174]\]. There was no difference in carbohydrate/fiber intake or dietary fiber intake among the different groups for eating speed in women. These results suggest that women with T2DM were able to consume a better-balanced diet regardless of the eating speed. Consuming a good-quality diet in any group differing by eating speeds may have influenced the lack of an association between eating speed and the presence of NAFLD.

In this study, the presence of NAFLD was associated with HbA1c in men. A previous study reported that HbA1c levels were significantly correlated with NAFLD \[[@B45-nutrients-12-02174]\]. A previous study revealed that aging is a risk factor for NAFLD in premenopausal women \[[@B46-nutrients-12-02174]\]. In this study, women with NAFLD were significantly younger. This might be because that all of the participants in the study were type 2 diabetes, and the effect of diabetes on NAFLD is greater than that of age.

However, there were certain limitations to our study. First, we did not check the patients' eating speed directly and depended on answers provided by them. Additionally, the number of chews was not examined in this study. However, a self-reported eatingspeed has been shown to be well-correlated with that reported by a friend or one that is objectively measured \[[@B10-nutrients-12-02174],[@B11-nutrients-12-02174],[@B47-nutrients-12-02174]\]. Second, although liver biopsy is the gold standard for diagnosing NAFLD, we did not perform it in this study. Furthermore, NAFLD was not diagnosed using fibroscan, MRI or ultrasound, although liver ultrasound is still the most convincing one for the diagnosis of fatty liver among non-invasive techniques \[[@B48-nutrients-12-02174]\]. However, HSI is correlated with definition of NAFLD using ultrasound \[[@B28-nutrients-12-02174]\]. Third, this is a cross-sectional study; thus, we cannot reveal a causal effect. Finally, this study included only Japanese patients; generalization to other ethnic groups is hence uncertain.

In conclusion, to the best of our knowledge, this study showed that eating speed is associated with the presence of NAFLD in men but not in women. Our study indicated that eating habits such as eating fast should be changed; if not, at least, the quality of diet should be improved, such as eating more fiber, which is desirable.
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nutrients-12-02174-t001_Table 1

###### 

Clinical characteristic of study patients.

                                          All            Men            Women          *p*
  --------------------------------------- -------------- -------------- -------------- ---------
                                          308            149 (48.4%)    159 (51.6%)    
  Age (years)                             66.8 (10.6)    67.6 (10.8)    66.1 (10.4)    0.320
  BMI (kg/m^2^)                           24.2 (4.0)     23.9 (3.0)     24.6 (4.7)     0.475
  Duration of diabetes (years)            14.4 (10.2)    15.5 (9.7)     13.3 (10.6)    0.008
  SBP (mm Hg)                             133.8 (18.8)   132.6 (17.6)   135.0 (19.8)   0.386
  DBP (mm Hg)                             78.5 (11.3)    78.7 (10.8)    78.3 (11.8)    0.351
  Hemoglobin A1c (%)                      7.3 (1.2)      7.3 (1.2)      7.3 (1.2)      0.951
  Hemoglobin A1c (mmol/mol)               56.5 (13.6)    56.7 (13.6)    56.4 (13.5)    0.951
  Glucose (mmol/L)                        8.1 (2.6)      8.3 (2.4)      8.0 (2.8)      0.186
  Total cholesterol (mmol/L)              5.0 (1.2)      4.8 (0.9)      5.1 (1.3)      \<0.001
  Triglyceride (mmol/L)                   1.5 (0.8)      1.5 (0.9)      1.5 (0.8)      0.701
  AST (IU/L)                              22.8 (9.6)     24.0 (10.6)    21.7 (8.5)     0.014
  ALT (IU/L)                              23.3 (14.5)    25.6 (15.3)    21.2 (13.5)    0.001
  γ-GTP (IU/L)                            32.7 (32.0)    37.0 (40.8)    28.6 (20.1)    0.018
  HSI (point)                             35.3 (5.9)     34.2 (4.8)     36.4 (6.7)     0.006
  Habit of exercise                       \-             \-             \-             0.211
  No                                      155 (50.3%)    69 (46.3%)     86 (54.1%)     \-
  Yes                                     153 (49.7%)    80 (53.7%)     73 (45.9%)     \-
  Habit of smoking                        \-             \-             \-             0.002
  No                                      270 (87.7%)    121 (81.2%)    149 (93.7%)    \-
  Yes                                     38 (12.3%)     28 (18.8%)     10 (6.3%)      \-
  Insulin treatment                       \-             \-             \-             0.827
  No                                      235 (76.3%)    115 (77.2%)    120 (75.5%)    \-
  Yes                                     73 (23.7%)     34 (22.8%)     39 (24.5%)     \-
  Fatty liver                                                                          0.016
  No                                      195 (63.3%)    105 (70.5%)    90 (56.6%)     \-
  Yes                                     113 (36.7%)    44 (29.5%)     69 (43.4%)     \-
  Eating speed                            \-             \-             \-             0.340
  Fast                                    145 (47.1%)    75 (50.3%)     70 (44.0%)     \-
  Moderate                                112 (36.4%)    48 (32.2%)     64 (40.3%)     \-
  Slow                                    51 (16.6%)     26 (17.4%)     25 (15.7%)     \-
  Total energy intake (kcal/kg IBW/day)   29.8 (10.1)    30.0 (9.0)     29.7 (11.1)    0.426
  Protein intake (% Energy)               17.1 (3.4)     16.3 (3.1)     17.9 (3.6)     \<0.001
  Fat intake (% Energy)                   29.2 (6.2)     28.5 (6.3)     29.8 (6.0)     0.022
  Carbohydrate intake (% Energy)          52.0 (8.3)     52.9 (8.4)     51.1 (8.2)     0.033
  Dietary fiber intake (g/day)            12.3 (4.9)     12.9 (5.1)     11.8 (4.7)     0.047
  Carbohydrate/fiber                      19.0 (6.9)     20.4 (7.6)     17.7 (6.0)     \<0.001

Data are expressed as mean (standard deviation) or number. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase; HSI, hepatic steatosis index. The differences of characteristics between patients by sex were evaluated by Mann-Whitney *u* test or Chi-squared test.

nutrients-12-02174-t002_Table 2

###### 

The characteristics of the patients according to eating speed.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
                                 Men                Women                                                                                                  
  ------------------------------ ------------------ ------------------ ------------------ ------- ------------------ ------------------ ------------------ -------
                                 Fast,\             Moderate,\         Slow,\             *p*     Fast,\             Moderate,\         Slow,\             *p*
                                 *n* = 75 (50.3%)   *n* = 48 (32.2%)   *n* = 26 (17.4%)           *n* = 70 (44.0%)   *n* = 64 (40.3%)   *n* = 25 (15.7%)   

  Age (years)                    66.3 (11.0)        67.1 (10.7)        72.5 (9.4) \*      0.012   65.7 (11.1)        65.3 (10.0)        69.2 (9.6)         0.109

  BMI (kg/m^2^)                  24.3 (2.9)         24.1 (3.0)         22.2 (2.6) \*      0.007   25.3 (4.9)         24.2 (4.5)         23.6 (4.7)         0.147

  Duration of diabetes (years)   15.6 (10.3)        15.9 (9.2)         14.8 (9.1)         0.891   13.5 (10.2)        12.0 (10.3)        16.0 (12.4)        0.244

  SBP (mm Hg)                    133.2 (16.3)       134.2 (19.7)       128.2 (17.1)       0.421   137.0 (20.5)       132.5 (19.6)       135.7 (18.1)       0.442

  DBP (mm Hg)                    78.9 (9.7)         80.5 (12.1)        74.7 (10.6)        0.186   78.9 (12.5)        77.8 (11.4)        77.7 (11.1)        0.886

  HbA1c (%)                      7.3 (1.2)          7.4 (1.6)          7.3 (0.8)          0.475   7.4 (1.1)          7.3 (1.5)          7.1 (0.7)          0.358

  HbA1c (mmol/mol)               56.5 (12.6)        57.1 (17.2)        56.4 (8.6)         0.475   57.4 (11.6)        56.4 (16.9)        54.0 (8.1)         0.358

  Glucose (mmol/L)               8.1 (2.4)          8.4 (2.5)          8.4 (2.5)          0.577   8.1 (3.0)          8.0 (2.5)          7.9 (2.7)          0.947

  Total cholesterol (mmol/L)     4.8 (0.9)          4.6 (1.0)          4.9 (0.7)          0.135   5.1 (1.4)          5.0 (1.4)          5.4 (0.9)          0.531

  Triglyceride (mmol/L)          1.5 (0.8)          1.6 (0.9)          1.3 (0.9)          0.201   1.5 (0.8)          1.5 (1.0)          1.3 (0.6)          0.670

  AST (IU/L)                     24.5 (12.3)        23.6 (9.6)         23.5 (6.0)         0.716   22.0 (7.1)         22.4 (10.8)        19.3 (3.9)         0.329

  ALT (IU/L)                     27.2 (17.5)        23.9 (12.6)        24.1 (13.1)        0.762   22.0 (12.3)        22.1 (16.3)        16.4 (5.7)         0.127

  γ-GTP (IU/L)                   39.5 (50.1)        33.5 (29.1)        36.3 (27.9)        0.722   27.8 (18.7)        31.1 (21.3)        24.2 (20.7)        0.043

  HSI (point)                    35.0 (5.0)         34.2 (4.3)         32.2 (4.5)         0.047   37.0 (6.3)         36.2 (7.5)         34.5 (5.0)         0.115

  Habit of exercise              \-                 \-                 \-                 0.266   \-                 \-                 \-                 0.491

  No                             34 (45.3%)         26 (54.2%)         9 (34.6%)          \-      38 (54.3%)         32 (50.0%)         16 (64.0%)         \-

  Yes                            41 (54.7%)         22 (45.8%)         17 (65.4%)         \-      32 (45.7%)         32 (50.0%)         9 (36.0%)          \-

  Habit of smoking               \-                 \-                 \-                 0.331   \-                 \-                 \-                 0.166

  No                             52 (82.7%)         36 (75.0%)         23 (88.5%)         \-      63 (90.0%)         61 (95.3%)         25 (100.0%)        \-

  Yes                            13 (17.3%)         12 (25.0%)         3 (11.5%)          \-      7 (10.0%)          3 (4.7%)           0 (0.0%)           \-

  Insulin treatment              \-                 \-                 \-                 0.500   \-                 \-                 \-                 0.795

  No                             58 (77.3%)         39 (81.2%)         18 (69.2%)         \-      52 (74.3%)         50 (78.1%)         18 (72.0%)         \-

  Yes                            17 (22.7%)         9 (18.8%)          8 (30.8%)          \-      18 (25.7%)         14 (21.9%)         7 (28.0%)          \-

  Fatty liver                    \-                 \-                 \-                 0.041   \-                 \-                 \-                 0.422

  No                             47 (62.7%)         35 (72.9%)         23 (88.5%)         \-      37 (52.9%)         36 (56.2%)         17 (68.0%)         \-

  Yes                            28 (37.3%)         13 (27.1%)         3 (11.5%)          \-      33 (47.1%)         28 (43.8%)         8 (32.0%)          \-

  Total energy intake\           31.2 (9.9)         28.7 (7.5)         28.8 (8.3)         0.402   29.1 (9.3)         29.8 (10.8)        31.2 (16.1)        0.993
  (kcal/kg IBW/day)                                                                                                                                        

  Protein intake (% Energy)      15.9 (2.8)         16.6 (3.3)         17.0 (3.2)         0.325   17.6 (3.4)         18.4 (3.9)         17.1 (3.0)         0.312

  Fat intake (% Energy)          27.9 (6.4)         29.5 (6.3)         28.7 (6.3)         0.371   30.3 (6.0)         29.6 (5.9)         29.1 (6.4)         0.722

  Carbohydrate intake\           53.6 (8.4)         52.0 (8.4)         52.1 (8.2)         0.552   51.0 (8.1)         50.6 (8.1)         53.0 (8.6)         0.573
  (% Energy)                                                                                                                                               

  Dietary fiber intake (g/day)   12.6 (5.4)         13.1 (5.4)         13.3 (3.9)         0.453   11.5 (4.7)         11.7 (4.3)         12.9 (5.5)         0.682

  Carbohydrate/fiber             22.3 (8.3)         19.0 (6.3)         17.7 (6.4)         0.002   17.8 (6.0)         17.8 (6.0)         17.0 (6.1)         0.924
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

\*, *p* \< 0.017 Fast vs. Slow. Data are expressed as mean (standard deviation) or number. BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin A1c; AST, aspartate aminotransferase; ALT, alanine aminotransferase; γ-GTP, gamma-glutamyl transpeptidase; HSI, hepatic steatosis index. The differences of characteristics between patients with different eating speed were evaluated by Kruskal-Wallis test or Chi-squared test.
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###### 

Logistic regression analysis on the presence of fatty liver.

  ---------------------------------------------------------------------------------------------------------------------------
  All                               Model 1             Model 2   Model 3                                           
  --------------------------------- ------------------- --------- ------------------- --------- ------------------- ---------
                                    OR (95% CI)         *p*       OR (95%CI)          *p*       OR (95% CI)         *p*

  Eating speed                                                                                                      

  Fast                              2.64 (1.25--5.56)   0.011     2.13 (0.95--4.81)   0.068     2.10 (0.90--4.91)   0.087

  Moderate                          2.10 (0.97--4.54)   0.060     1.45 (0.62--3.38)   0.390     1.42 (0.59--3.44)   0.436

  Slow                              Ref                 \-        Ref                 \-        Ref                 \-

  Women                             \-                  \-        1.87 (1.08--3.22)   0.025     1.59 (0.90--2.81)   0.108

  Age (years)                       \-                  \-        0.95 (0.92--0.97)   \<0.001   0.95 (0.92--0.98)   \<0.001

  Duration of diabetes (years)      \-                  \-        0.95 (0.92--0.98)   0.002     0.95 (0.92--0.98)   0.001

  Hemoglobin A1c (mmol/mol)         \-                  \-        1.33 (1.04--1.71)   0.022     1.32 (1.03--1.69)   0.027

  Energy intake (kcal/kg IBW/day)   \-                  \-        \-                  \-        1.03 (1.00--1.06)   0.079

  Carbohydrate intake\              \-                  \-        \-                  \-        1.00 (0.97--1.03)   0.987
  (% Energy)                                                                                                        

  Dietary fiber intake (g/day)      \-                  \-        \-                  \-        0.91 (0.85--0.98)   0.011

  Habit of exercise                 \-                  \-        1.10 (0.65--1.87)   0.713     1.13 (0.66--1.94)   0.662

  Habit of smoking                  \-                  \-        1.47 (0.67--3.26)   0.340     1.37 (0.62--3.05)   0.440

  Insulin treatment                 \-                  \-        0.71 (0.36--1.38)   0.311     0.77 (0.39--1.53)   0.456

  Men                               Model 1             Model 2   Model 3                                           

                                    OR (95% CI)         *p*       OR (95%CI)          *p*       OR (95% CI)         *p*

  Eating speed                                                                                                      

  Fast                              4.57 (1.26--16.6)   0.021     4.34 (1.08--17.4)   0.038     4.48 (1.09--18.5)   0.038

  Moderate                          2.85 (0.73--11.1)   0.132     2.73 (0.61--12.1)   0.186     2.97 (0.66--13.4)   0.156

  Slow                              Ref                 \-        Ref                 \-        Ref                 \-

  Age (years)                       \-                  \-        0.96 (0.92--1.00)   0.045     0.96 (0.92--1.00)   0.063

  Duration of diabetes (years)      \-                  \-        0.94 (0.89--0.99)   0.017     0.93 (0.88--0.99)   0.014

  Hemoglobin A1c (mmol/mol)         \-                  \-        1.14 (0.43--3.02)   0.798     1.04 (1.00--1.08)   0.031

  Energy intake (kcal/kg IBW/day)   \-                  \-        \-                  \-        1.00 (0.95--1.06)   0.865

  Carbohydrate intake\              \-                  \-        \-                  \-        0.99 (0.94--1.04)   0.558
  (% Energy)                                                                                                        

  Dietary fiber intake (g/day)      \-                  \-        \-                  \-        0.95 (0.86--1.05)   0.351

  Habit of exercise                 \-                  \-        2.05 (0.89--4.76)   0.093     2.09 (0.88--4.93)   0.094

  Habit of smoking                  \-                  \-        1.14 (0.43--3.02)   0.798     1.04 (0.39--2.79)   0.940

  Insulin treatment                 \-                  \-        0.51 (0.18--1.51)   0.225     0.56 (0.18--1.69)   0.300

  Women                             Model 1             Model 2   Model 3                                           

                                    OR (95% CI)         *p*       OR (95%CI)          *p*       OR (95% CI)         *p*

  Eating speed                                                                                                      

  Fast                              1.90 (0.72--4.96)   0.193     1.33 (0.45--3.95)   0.606     1.30 (0.39--4.31)   0.665

  Moderate                          1.65 (0.62--4.38)   0.312     1.07 (0.35--3.23)   0.906     0.92 (0.28--3.09)   0.896

  Slow                              Ref                 \-        Ref                 \-        Ref                 \-

  Age (years)                       \-                  \-        0.93 (0.90--0.97)   0.001     0.94 (0.90--0.98)   0.006

  Duration of diabetes (years)      \-                  \-        0.95 (0.91--0.99)   0.025     0.95 (0.90--0.99)   0.018

  Hemoglobin A1c (mmol/mol)         \-                  \-        1.01 (0.98--1.04)   0.429     1.01 (0.98--1.04)   0.513

  Energy intake (kcal/kg IBW/day)   \-                  \-        \-                  \-        1.05 (1.00--1.09)   0.044

  Carbohydrate intake\              \-                  \-        \-                  \-        1.01 (0.96--1.06)   0.743
  (% Energy)                                                                                                        

  Dietary fiber intake (g/day)      \-                  \-        \-                  \-        0.85 (0.76--0.96)   0.010

  Habit of exercise                 \-                  \-        0.63 (0.31--1.31)   0.216     0.65 (0.30--1.40)   0.272

  Habit of smoking                  \-                  \-        3.08 (0.64--14.8)   0.160     3.30 (0.67--16.2)   0.142

  Insulin treatment                 \-                  \-        0.91 (0.36--2.27)   0.836     0.92 (0.35--2.40)   0.868
  ---------------------------------------------------------------------------------------------------------------------------

All, Model 1 is unadjusted; Model 2 is adjusted for sex, age, duration of diabetes, hemoglobin A1c, habit of exercise, habit of smoking, insulin treatment; and Model 3 is adjusted for sex, age, duration of diabetes, hemoglobin A1c, energy intake, carbohydrate intake, dietary fiber intake, habit of exercise, habit of smoking, insulin treatment. Men and women, Model 1 is unadjusted; Model 2 is adjusted for age, duration of diabetes, hemoglobin A1c, habit of exercise, habit of smoking, insulin treatment; and Model 3 is adjusted for age, duration of diabetes, hemoglobin A1c, energy intake, carbohydrate intake, dietary fiber intake, habit of exercise, habit of smoking, insulin treatment.
